SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
Citi's 18th Annual BioPharma Conference on Thursday, September 7, 2023 in Boston, Massachusetts
- Hosting 1x1 investor meetings only
Wells Fargo 2023 Healthcare Conference on Friday, September 8, ...